Giving sight back to those who have lost it due to glaucoma is a noble cause. If Sinclair pulls it off, it will more than make up for any of his other failings.
I hope he pulls it off as it will change the world AND be a big step towards increased longevity through cellular reprogramming.
As far as I know, it cleared the FDA for human clinical trials back in late January, and they actually dosed the first subject last month. The drug candidate is coded ER-100. Honestly, this is a much bigger deal than you might think—the only reason they filed it for glaucoma is because the FDA doesn’t recognize ‘anti-aging’ as a valid clinical indication yet.